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Introduction
Respiratory syncytial virus (RSV) was first isolated from
American children with pulmonary disease in 1957 [1],
and it is now recognized as the most important cause of
viral lower respiratory tract disease in infants and children
worldwide [2–4]. RSV is the largest single cause of child-
hood hospitalization and is therefore a major drain on
public health resources [5]. Furthermore, recent data from
the USA [6] suggest that rates of hospitalization due to
RSV infections are increasing. A Danish study [7] found
the incidence of RSV infection requiring hospitalization
during the 1995–1996 winter season to be 34/1000 in
infants younger than 6 months. Not many Danish RSV epi-
demiological studies have been conducted, however, and
the few studies reported thus far were conducted in
limited geographical areas [8].
High-risk groups for severe RSV infection include infants
born prematurely [9]; children with congenital hearth
disease [10], cystic fibrosis [11], or other chronic lung dis-
eases [12]; immunosuppressed patients or patients with
congenital immunodeficiency [13]; individuals living in
institutions; and the elderly [14,15]. Hence, children dis-
charged from neonatal intensive care units are at risk for
rehospitalization from RSV infection [16]. However, the
majority of infants who develop severe RSV disease were
born at term and are otherwise healthy. Among those,
certain factors have been associated with severe disease:
month of birth, age younger than 6 months, male sex, eth-
nicity [17], low socioeconomic status, crowded living con-
ditions, number of siblings, indoor smoke pollution,
day-care attendance [18], and a family history of asthma
and atopy [19,20]. Many studies suggest that passively
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acquired maternal antibody confers protection against
severe RSV disease [21,22], and incomplete transfer of
maternally derived antibodies has been proposed as a
contributing factor to the increased risk for RSV infection
that is observed in preterm infants [9]. Breast-feeding also
protects against severe RSV infection [21,23].
Within the first year following severe, hospital-requiring
RSV infection, up to 20% of children are rehospitalized
because of wheezing [24]. RSV bronchiolitis has been
associated with abnormal pulmonary function, wheezing
and asthmatic tendencies in children up to age 11 years
[25,26]. Hospitalization-requiring RSV bronchiolitis during
the first year of life has been found to be an important risk
factor in children up to age 7 years for development not
only of asthma but also of sensitization to common aller-
gens, particularly in individuals with a genetic predisposi-
tion to atopy [27].
Recent studies suggest that severe RSV infection is associ-
ated with a Th2 cell response [28] and that enhanced lung
pathology during RSV infection is associated with local
release of Th2 cytokines [29]. Therefore, it is likely that a
Th2 profile facilitates infection and immunopathogenesis, or
limits protective responses. The immune system of the
newborn child is usually Th2 biased [30,31], and this may
partly explain why RSV infection is particularly severe during
the first 6 months of life. Likewise, atopy is associated with a
Th2 profile [32,33], and this may explain why severe RSV
infection is associated with a family history of atopy and
asthma [19].
In recent decades there has been an increase in atopic
disease, which appears to be related to an increasing
Th2 bias in the immunological profile. In contrast, we
found that a strong reaction (scar) to bacille
Calmette–Guérin vaccination (a promoter of a Th1 profile
[34]) was protective against RSV disease in Guinea-
Bissau, because not having a scar was twice as common
among children with RSV lower respiratory tract infection
than among control children (Stensballe LG, unpublished
data). Furthermore, bacille Calmette–Guérin vaccination
prevents atopy [35].
A relationship between prior RSV infection, wheezing and
atopic disease has frequently been reported, but it is not
known whether this is a causal association or due to
common determinants of the two conditions. Above all,
the way in which we influence our disease patterns and
how we interact with our surroundings may have conse-
quences for our immunological profile and RSV morbidity.
Recently, we found that caesarean section increases the
risk for atopic disease [36], and another study [37]
showed an association between early childhood use of
antibiotics and increased risk for developing asthma and
allergic disease in predisposed children. If the association
between severe RSV infection and atopy is in part
explained by a common immunological bias, then the
same factors (i.e. vaccination history, caesarean section
and use of antibiotics) might influence the risk for severe
RSV infection.
Exposure intensity has been found to be a determinant of
infection or severity of several diseases, including
measles [38], chickenpox, polio and whooping cough.
Crowding, large family size, multiple birth, small living
quarters and day-care attendance facilitate intensive
exposure, and these factors are usually found to be risk
factors for severe disease. It appears likely that this also
applies to RSV.
Because cross-sex transmission increases severity of
infection in measles [39], chickenpox and polio [40], part
of the reason why boys are more likely to contract severe
infection may be that mothers are more likely to transmit
RSV to their sons. In Guinea-Bissau, among children with
lower respiratory tract infection, we found that boys were
twice as likely as girls to have an RSV antigen positive
infection if the mother had an RSV-IgM or RSV-IgA
response, indicating recent infection (Stensballe LG,
unpublished data).
Attempts to develop a safe and effective RSV vaccine
have met with failure. Likewise, there is no treatment avail-
able against severe RSV infection. Prophylaxis with the
humanized monoclonal antibody palivizumab can reduce
risk for hospitalization for RSV disease in high-risk infants
[41–43], but the drug is expensive. A recent study [44]
showed that this antibody can prevent RSV-induced
neurogenic inflammation of mouse airways when given
before or in the early phase of infection. If this also applies
to humans then passive prophylaxis or immunization of
pregnant women might prevent not only severe RSV infec-
tion but also wheezing.
Research questions
Aim 1
Our first objective is to conduct a study to validate RSV
associated diagnoses in the Danish National Patient Reg-
istry (DNPR). This validation will enable us to assess
whether the incidence of severe RSV is increasing. The
analyses will determine the reliability of the RSV-specific
categories in the DNPR and how well these cover the full
range of RSV infections that lead to hospitalization. The
worst case scenario would be that the DNPR data are
impossible to use, and we would then have to base our
epidemiological studies exclusively on patients with a pos-
itive laboratory diagnosis of RSV. It is more likely that
certain clinical RSV categories are reasonably reliable but
do not cover the full range of RSV infections. The study
will at least provide a good basis for standardizing classifi-
cation of RSV infections in the future.S36
Respiratory Research    Vol 3 Suppl 1 Stensballe
Aim 2
A prerequisite for rational use of currently available prophy-
lactic and preventive measures and vaccines, when they
become available, is a better understanding of the factors
that promote or prevent severe RSV infection. Apart from
examining the role of conditions that are known to be risk
factors for severe RSV infections in other Western coun-
tries, we wish to examine some new factors associated with
RSV infections. We will examine whether factors that facili-
tate transmission of viral respiratory infections, and whether
caesarean section, use of antibiotics and vaccination history
contribute to RSV infection. We will also measure the inci-
dence of nosocomial RSV infection and determine risk
factors for nosocomial infection. In addition, we intend to
determine the level of maternal RSV antibodies in cord
blood that is needed to confer protection against disease
during the first critical months of life. This information will be
applied to maternal vaccination programmes.
Aim 3
We intend to examine several issues in order to address
the link between severe RSV infection, wheezing and
atopy: the chronological relation between RSV infections
and wheezing; the incidence of rehospitalization for
wheezing after RSV infection and risk factors for rehospi-
talization; the chronological relation between RSV infec-
tions and atopic dermatitis; whether risk factors for atopy
are also risk factors for severe RSV infection; whether an
atopic profile (determined as specific IgE in serum) is
more common among mothers of children who are hospi-
talized with RSV than among mothers of control children;
whether the level of total IgE in cord blood is an indicator
of atopic profile among children hospitalized with RSV in
comparison with control children; and whether a high level
of maternal RSV antibodies in cord blood is protective
against RSV hospitalization and wheezing.
Materials and method
The personal identification number
Since 1968 a personal identification number has been
assigned to every Danish citizen and registered in the
Central Person Register (CPR). This personal identifica-
tion number provides a unique ability for epidemiological
research in the Danish population by facilitating reliable
linkage of person-identifiable information between various
registers. The personal identification number serves as the
key reference to the individual in all registry relations and
provides a simple method for linking registry information.
Validation of the diagnostic coding in the Danish
National Patient Registry
Most children younger than 2 years who are hospitalized
with symptoms of a respiratory infection will have a sample
of nasal secretion taken (a nasopharyngeal aspirate) to
confirm the diagnosis. Thirteen microbiological depart-
ments and the Statens Serum Institut perform and register
microbiological identification of RSV infections in
Denmark. Virus detection is the ‘gold standard’ for RSV
diagnosis. There are reasons to believe that this may lead
to under-diagnosis of RSV infection, however, because
virus is only detectable during the first few days of infec-
tion. In Guinea-Bissau, for example, using an enzyme-
linked immunosorbent assay to detect secretory RSV IgM,
38% of lower respiratory infections were associated with
RSV, as opposed to the 17% identified using only an
enzyme-linked immunosorbent assay for the antigen [45].
Every patient discharged from a Danish hospital is regis-
tered in the DNPR. Among the information entered into
the DNPR are diagnoses, which have to be selected from
the 10th revision of the International Statistical Classifica-
tion of Diseases and Related Health Problems [46]. That
classification has four RSV-specific diagnoses, as well as
a rich variety of diagnoses that may cover the symptoms of
an RSV infection. As noted by the Danish National Health
Service, there is considerable variation in how different
paediatric departments enter their diagnoses [47]. It is
therefore important to know not only how RSV-positive
cases are registered in DNPR but also how clinically sus-
pected RSV cases are classified. To be able to use the
DNPR for epidemiological studies, we need to identify the
pattern of classification of diagnoses.
The Danish Respiratory Syncytial Virus Database
Through the 13 microbiological departments and the
Statens Serum Institut, we have established a database
with information on RSV analyses and the personal identi-
fication numbers of people tested for RSV in Denmark
since 1996. To date, the database contains information on
10,870 RSV-positive and 23,064 RSV-negative samples.
Of the RSV-positive findings, 67% (7265) were in infants.
The male:female ratio in RSV-positive findings is 1.3:1
(6117/4643; 110 missing values). Distributions of sex and
age in the 10,458 RSV-positive findings in children
younger than 3 years old are presented in Fig. 1.
Through the DNPR, we will collect hospitalization informa-
tion on these individuals as well as on all those with RSV-
specific diagnoses since 1996 who are not already in the
laboratory register. The proposed analyses will determine
the reliability of the RSV-specific categories in the DNPR
and will indicate how well these cover the full range of
RSV infections that lead to hospitalization. Furthermore,
the study will provide a good basis for standardizing clas-
sification of RSV infections in the future. Above all, we
intend to examine whether there has been an increase in
RSV-hospitalized cases during the study period
(1996–2001), as has been observed in the USA [6].
Birth cohorts
The role of various biological, social and environmental
factors will be studied through various population-basedS37
registers, the two major ones being the Danish National
Birth Cohort (which has documented a large number of
exposure variables) and the Danish child population in the
CPR register. The main outcome to be evaluated will be
hospitalization associated with RSV infection, as defined
either by a positive RSV sample in the Danish RSV Data-
base or by a reliable clinical diagnosis in the DNPR, as
defined by the validation study described above. Nosoco-
mial infection will be defined as RSV infection diagnosed
after 4 or more days of an inpatient stay when hospitaliza-
tion is for other reasons.
The Danish National Birth Cohort
In 1997, the Danish Epidemiology Science Centre,
Statens Serum Institut, initiated The Danish National Birth
Cohort: ‘Better health for mothers and children’. Since
1997, women have been invited to participate in the study
if they speak Danish and intend to carry their pregnancies
to term. At April 2002, approximately 95,000 pregnant
women had been enrolled. Participation involves four com-
puter-assisted telephone interviews in weeks 12 and 30 of
pregnancy (1st and 2nd interviews), and 6 and 18 months
after delivery (3rd and 4th interviews). Information on
health, lifestyle, socioeconomic status throughout preg-
nancy, and delivery is collected. Data regarding feeding
habits, diseases, medication, vaccinations, motor and cog-
nitive development, anthropometrics, and day-care atten-
dance are obtained on the child. The age at which illness
is contracted is registered. Blood samples are collected
from the pregnant women in weeks 12 and 24, and cord
blood samples are obtained at birth.
The Danish child population
Through the CPR, we will construct a cohort of children
born in Denmark between 1996 and 2002 that can be
linked with the laboratory database, as well as with the
DNPR, in order to identify individuals who had severe RSV
infection leading to hospitalization. It is estimated that this
cohort will include around 390,000 children. Data regard-
ing potential risk factors, protective factors and con-
founders will be obtained from the Medical Birth Registry,
the DNPR and other public registers, including information
on social conditions, day-care attendance, immunizations
and medication.
Depending on the research question, the RSV hospitaliza-
tion cases will be compared with controls selected within
the same population groups on a case–control or a cohort
basis to produce estimates of age-adjusted and sex-
adjusted relative risks (odds ratio and relative risk) for hos-
pitalization associated with different factors of interest.
The choice between the Danish National Birth Cohort and
this child population for the analyses will depend on differ-
ent factors including quality of information on exposure,
facility of access, and the prevalence of the factor under
study.
Sample size considerations
Based on two recent Danish studies that found the inci-
dence of RSV infection requiring hospitalization to be
34/1000 for infants younger than 6 months and 14/1000
for those younger that 3 years, we estimate that 2% of
children below 2 years of age will be hospitalized for RSV
disease. With an annual birth cohort of 65,000 and
390,000 children born between 1996 and 2002, we are
likely to identify approximately 7800 RSV-related hospital-
izations during this period. This sample size should aid in
the detection of even small additional risks in studies of
the total population. Sample size for the studies involving
biological materials will be calculated on the basis of pilot
studies to determine the level of atopy and RSV antibod-
ies in the current Danish population of mothers.
Timetable
The study was initiated in January 2001, at which time we
began data collection and the validation study, and will
last until December 2005.
Ethics
The study is noninterventional and does not require further
contact with individuals once they are registered either at
the microbiological departments or in the Danish National
Birth Cohort. Therefore, further informed consent is not
required. Only anonymous data will be reported.
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